acetylleucyl-leucyl-norleucinal has been researched along with Cardiomyopathies in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burukoğlu, D; Kanbak, G; Kartkaya, K; Oğlakçı, A; Ozer, MC | 1 |
| Campos, EC; Celes, MR; Figueiredo, MJ; Freitas, AC; Ramos, SG; Soave, DF; Tanowitz, HB | 1 |
| Chopin, C; Depontieu, F; Lancel, S; Marechal, X; Mordon, S; Neviere, R; Scherpereel, A; Tissier, S | 1 |
3 other study(ies) available for acetylleucyl-leucyl-norleucinal and Cardiomyopathies
| Article | Year |
|---|---|
Protective effect of calpain inhibitor N-acetyl-L-leucyl-L-leucyl-L-norleucinal on acute alcohol consumption related cardiomyopathy.
Topics: Animals; Binge Drinking; Calpain; Cardiomyopathies; Caspase 3; Cathepsin B; Cathepsin L; Creatine Kinase, MB Form; Cysteine Proteinase Inhibitors; Cytochromes c; Disease Models, Animal; Humans; Immunohistochemistry; Leupeptins; Male; Myocardium; Nerve Tissue Proteins | 2014 |
Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition.
Topics: Actins; Animals; Calpain; Cardiomyopathies; Disease Models, Animal; Dystrophin; Gene Expression; Leupeptins; Male; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Myocardium; Myosins; Proteasome Endopeptidase Complex; Proteolysis; Sepsis; TOR Serine-Threonine Kinases; Ubiquitin | 2016 |
Calpain inhibitors improve myocardial dysfunction and inflammation induced by endotoxin in rats.
Topics: Animals; Cardiomyopathies; Endotoxins; Glycoproteins; Heart; In Vitro Techniques; Inflammation; Injections, Intravenous; Leukocyte Rolling; Leupeptins; Male; Myocardial Contraction; Myocardium; Nitrates; Nitrites; Rats; Rats, Sprague-Dawley; Shock, Septic; Tumor Necrosis Factor-alpha | 2004 |